517 related articles for article (PubMed ID: 17067392)
21. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells.
Gubbels JA; Felder M; Horibata S; Belisle JA; Kapur A; Holden H; Petrie S; Migneault M; Rancourt C; Connor JP; Patankar MS
Mol Cancer; 2010 Jan; 9():11. PubMed ID: 20089172
[TBL] [Abstract][Full Text] [Related]
22. Transcriptional control of the MUC16 promoter facilitates follicle-stimulating hormone peptide-conjugated shRNA nanoparticle-mediated inhibition of ovarian carcinoma in vivo.
Zhang MX; Hong SS; Cai QQ; Zhang M; Chen J; Zhang XY; Xu CJ
Drug Deliv; 2018 Nov; 25(1):797-806. PubMed ID: 29542355
[TBL] [Abstract][Full Text] [Related]
23. [MUC16: The Novel Target for Tumor Therapy].
Gao R; Lou N; Han X; Shi Y
Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):452-459. PubMed ID: 35899441
[TBL] [Abstract][Full Text] [Related]
24. Mucins and Truncated
Coelho R; Marcos-Silva L; Mendes N; Pereira D; Brito C; Jacob F; Steentoft C; Mandel U; Clausen H; David L; Ricardo S
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011875
[TBL] [Abstract][Full Text] [Related]
25. [Tumor Marker CA125: biochemical and molecular properties].
Bouanène H; Miled A
Bull Cancer; 2009 May; 96(5):597-601. PubMed ID: 19435686
[TBL] [Abstract][Full Text] [Related]
26. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment.
Bergan L; Gross JA; Nevin B; Urban N; Scholler N
Cancer Lett; 2007 Oct; 255(2):263-74. PubMed ID: 17560019
[TBL] [Abstract][Full Text] [Related]
27. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells.
Comamala M; Pinard M; Thériault C; Matte I; Albert A; Boivin M; Beaudin J; Piché A; Rancourt C
Br J Cancer; 2011 Mar; 104(6):989-99. PubMed ID: 21326240
[TBL] [Abstract][Full Text] [Related]
28. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract][Full Text] [Related]
29. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
30. Mucin 16 is a functional selectin ligand on pancreatic cancer cells.
Chen SH; Dallas MR; Balzer EM; Konstantopoulos K
FASEB J; 2012 Mar; 26(3):1349-59. PubMed ID: 22159147
[TBL] [Abstract][Full Text] [Related]
31. Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway.
Huo Q; Xu C; Shao Y; Yu Q; Huang L; Liu Y; Bao H
Int J Biol Sci; 2021; 17(2):574-588. PubMed ID: 33613114
[No Abstract] [Full Text] [Related]
32. Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
Chen SH; Hung WC; Wang P; Paul C; Konstantopoulos K
Sci Rep; 2013; 3():1870. PubMed ID: 23694968
[TBL] [Abstract][Full Text] [Related]
33. Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer.
Aithal A; Junker WM; Kshirsagar P; Das S; Kaur S; Orzechowski C; Gautam SK; Jahan R; Sheinin YM; Lakshmanan I; Ponnusamy MP; Batra SK; Jain M
PLoS One; 2018; 13(4):e0193907. PubMed ID: 29708979
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.
Hassan R; Schweizer C; Lu KF; Schuler B; Remaley AT; Weil SC; Pastan I
Lung Cancer; 2010 Jun; 68(3):455-9. PubMed ID: 19744744
[TBL] [Abstract][Full Text] [Related]
35. Mucins MUC16 and MUC1 are major carriers of SLe(a) and SLe(x) in borderline and malignant serous ovarian tumors.
Ricardo S; Marcos-Silva L; Valente C; Coelho R; Gomes R; David L
Virchows Arch; 2016 Jun; 468(6):715-22. PubMed ID: 27003157
[TBL] [Abstract][Full Text] [Related]
36. Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
Rao TD; Tian H; Ma X; Yan X; Thapi S; Schultz N; Rosales N; Monette S; Wang A; Hyman DM; Levine DA; Solit D; Spriggs DR
PLoS One; 2015; 10(5):e0126633. PubMed ID: 25965947
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125).
Belisle JA; Gubbels JA; Raphael CA; Migneault M; Rancourt C; Connor JP; Patankar MS
Immunology; 2007 Nov; 122(3):418-29. PubMed ID: 17617155
[TBL] [Abstract][Full Text] [Related]
38. Antiadhesive character of mucin O-glycans at the apical surface of corneal epithelial cells.
Sumiyoshi M; Ricciuto J; Tisdale A; Gipson IK; Mantelli F; Argüeso P
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):197-203. PubMed ID: 18172093
[TBL] [Abstract][Full Text] [Related]
39. Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth.
Rao TD; Fernández-Tejada A; Axelrod A; Rosales N; Yan X; Thapi S; Wang A; Park KJ; Nemieboka B; Xiang J; Lewis JS; Olvera N; Levine DA; Danishefsky SJ; Spriggs DR
ACS Chem Biol; 2017 Aug; 12(8):2085-2096. PubMed ID: 28617578
[TBL] [Abstract][Full Text] [Related]
40. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Hassan R; Remaley AT; Sampson ML; Zhang J; Cox DD; Pingpank J; Alexander R; Willingham M; Pastan I; Onda M
Clin Cancer Res; 2006 Jan; 12(2):447-53. PubMed ID: 16428485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]